Products

FEops HEARTguide
FEops NV
Cardiology AI
FEops HEARTguide™ is a cloud-based AI and digital twin platform for structural heart procedure planning, providing predictive simulations and anatomical measurements to optimize device sizing and positioning for improved patient outcomes.
FEops HEARTguideTM
FEops nv
Cardiology AI
FEops HEARTguide™ is a cloud-based AI and digital twin platform for structural heart procedure planning, providing predictive simulations and anatomical insights to optimize device sizing and positioning for interventions like TAVI and LAAO.

See all 2 products →

About FEops nv

FEops nv, now a Materialise company, is a healthcare AI firm specializing in advanced pre-procedural planning for structural heart interventions. Their flagship product, FEops HEARTguide™, is a cloud-based platform that leverages cutting-edge predictive simulation technology and artificial intelligence to provide physicians with unprecedented insights into a patient’s total heart health. By analyzing cardiac computed tomography (CT) scans, the platform creates patient-specific ‘digital twins’—virtual replicas of the heart or its substructures.

For physicians, FEops HEARTguide™ offers critical data-driven insights that go beyond traditional anatomical measurements. It enables more accurate prediction of how transcatheter structural heart devices will interact with a specific patient’s anatomy, thereby improving procedure efficiency and outcomes. The platform supports planning for procedures such as Transcatheter Aortic Valve Implantation (TAVI/TAVR) and Left Atrial Appendage Occlusion (LAAO), with ongoing research and development in areas like Transcatheter Mitral Valve Replacement (TMVR). This technology aids in optimal device sizing and positioning, helping to reduce complications and enhance clinical decision-making.

Focus Areas

Structural heart disease Left Atrial Appendage Occlusion (LAAo) planning Transcatheter Aortic Valve Implantation (TAVI) planning predictive simulation digital twin technology AI-based anatomical analysis cardiovascular interventions personalized treatment

Business Intelligence

Key InvestorsCapricorn Partners, European Innovation Council (EIC Fund), Horizon 2020, Valiance, PMV, 3DEXPERIENCE Lab, European Commission
PartnershipsTeraRecon (commercialization of LAA occlusion workflow in US, Oct 2023)
AcquisitionsAcquired by Materialise on July 18, 2024
TechnologyCloud-based, digital twin technology, AI-enabled anatomical analysis, predictive simulation, finite element analysis (FEA)
FDA Clearances3 cleared products (estimated)

What Physicians Need to Know

Structural Heart Disease Planning
FEops HEARTguideu2122 is a cloud-based platform that redefines structural heart interventions by transforming cardiac images into digital twins for highly personalized treatment planning. It provides data-driven insights to improve procedure planning, efficiency, and outcomes across various structural heart therapies.
Left Atrial Appendage Occlusion (LAAo) Planning
The platform offers unique insights to make LAAo procedures more predictable, helping physicians select the optimal device size and position. Clinical studies (PREDICT-LAA) have shown it can lead to a reduction in the total number of closure devices used and a twofold increase in procedural success with a single device and deployment.
Transcatheter Aortic Valve Implantation (TAVI) Planning
FEops HEARTguideu2122 enables confident planning for complex TAVI cases, including understanding options for future valve-in-valve procedures. It helps assess risks like paravalvular leakage and conduction abnormalities by predicting device-anatomy interaction.
Predictive Simulation & Digital Twin Technology
At its core, FEops transforms cardiac images into patient-specific digital twins, allowing for detailed predictive simulations of how a transcatheter device will interact with a patient's unique anatomy before the procedure. This goes beyond traditional anatomical measurements to offer deeper insights into device-anatomy interaction.
AI-based Anatomical Analysis
The platform integrates AI-enabled anatomical analysis of MSCT images for fast, accurate, and semi-automated identification and measurement of anatomical landmarks. This streamlines workflows, saves time for heart teams, and provides consistent, quality-controlled data in minutes.
Personalized Treatment & Cardiovascular Interventions
FEops enables highly personalized treatment planning by allowing physicians to assess different treatment scenarios and optimize device selection and positioning for each patient. The company is expanding its pipeline to include personalized simulations for transcatheter tricuspid valve replacement (TTVR) and transcatheter mitral valve replacement (TMVR).
Physician Tip

Leverage FEops HEARTguideu2122 to gain unprecedented pre-operative insights into device-anatomy interaction, enabling optimal device sizing and positioning for LAAo and TAVI procedures. Utilize the AI-based anatomical analysis for faster, more accurate measurements and to streamline your planning workflow. The platform's predictive simulations can help assess and mitigate risks like paravalvular leakage or LVOT obstruction, leading to improved procedural efficiency and patient outcomes. Engage with the collaborative features to share cases securely with peers and industry partners for enhanced decision-making. Explore its potential for future interventions like TTVR and TMVR as they become clinically available.

FEops HEARTguideu2122 is a cloud-based platform accessible from anywhere, ensuring data confidentiality (GDPR and HIPAA compliant). It features a DICOM interface for easy integration of patient CT scans into the workflow. The platform leverages the Dassault Systu00e8mes 3DEXPERIENCE platform for scalability and advanced 3D multiphysics simulation. It also utilizes Materialise Mimics Innovation Suite for 3D reconstruction and segmentation, enhancing workflow automation.

Products by FEops nv

2 products in the directory

FEops HEARTguide
FEops NV
Cardiology AI
FEops HEARTguide™ is a cloud-based AI and digital twin platform for structural heart procedure planning, providing predictive simulations and anatomical measurements to optimize device sizing and positioning for improved patient outcomes.
FEops HEARTguideTM
FEops nv
Cardiology AI
FEops HEARTguide™ is a cloud-based AI and digital twin platform for structural heart procedure planning, providing predictive simulations and anatomical insights to optimize device sizing and positioning for interventions like TAVI and LAAO.

Reviews & Opinions

No web reviews on file yet for FEops nv. Check back later for aggregated opinions from across the web.

Videos

News, demos, and interviews about FEops nv.

Loading videos...

Videos load interactively. If none appear, search YouTube for FEops nv →

View all on YouTube

Press & Coverage

Materialise
Materialise Expands Cardiovascular Capabilities through FEops Acquisition
Materialise has acquired FEops, a Belgian company specializing in AI-driven simulation technology to enhance the efficiency and clinical outcomes of structural heart interventions. This acquisition aims to advance mass personalization in healthcare by using 3D technologies for tailored treatment plans.
2024-07
FEops HEARTguide Press Releases
Clinical utility of FEops AI-enabled predictive pre-planning for LAAO demonstrated in US
Data from the first US comprehensive single-center experience at St Bernard's Medical Center and Arrhythmia Research Group demonstrated that Left Atrial Appendage Occlusion (LAAO) procedures planned with FEops HEARTguideu2122 significantly improve efficiency and outcomes. This was presented at a Late-Breaking session at the AF Symposium 2024.
2024-02
FEops HEARTguide Press Releases
FEops Partners with TeraRecon to Scale the Commercialization of FEops HEARTguide, its Digital Twin Solution for an Elevated Structural Heart Experience
FEops announced a partnership with TeraRecon to expand the commercialization of FEops HEARTguide, their digital twin solution for structural heart procedures. This collaboration aims to scale the reach of their AI-enabled predictive planning technology.
2023-10
Business Wire
FEops Receives FDA Clearance for Its AI-Based Anatomical Analysis Capabilities
FEops announced a new release of FEops HEARTguideu2122 with AI-based anatomical analysis of MSCT images for pre-operative planning of structural heart interventions, receiving FDA clearance. This feature streamlines workflows by eliminating the need for manual measurements.
2023-06
BioWorld
Feops looks to raise u20ac10m, its Heartguide shown to significantly improve LAAC procedures
FEops NV is seeking to raise u20ac10 million in a Series C funding round to expand its global operations, following a study published in JACC: Cardiovascular Interventions that demonstrated its Heartguide platform significantly improved the efficiency and outcomes of left atrial appendage closure (LAAC) procedures.
2023-03
FEops HEARTguide Press Releases
FEops HEARTguide Proven to Significantly Enhance Efficiency and Outcomes of LAA Closure Procedures
FEops HEARTguide has been proven to significantly enhance the efficiency and outcomes of Left Atrial Appendage (LAA) closure procedures. This highlights the positive impact of their digital twin technology in structural heart interventions.
2023-02
FEops HEARTguide Press Releases
FEops' AI-enabled solution changes TAVI pre-procedural decision in one third of patients, associated with favorable clinical outcomes
FEops' AI-enabled solution for Transcatheter Aortic Valve Implantation (TAVI) pre-procedural planning has been shown to alter treatment decisions in one-third of patients, leading to favorable clinical outcomes. This underscores the impact of their technology on personalized patient care.
2022-11
JACC Advances
FEops HEARTguide Patient-Specific Computational Simulations for WATCHMAN FLX Left Atrial Appendage Closure: A Retrospective Study
This retrospective study demonstrated that the FEops HEARTguide model accurately predicts WATCHMAN FLX device implantation characteristics for left atrial appendage closure. The study suggests that computational modeling could improve confidence in device sizing and positioning.
2022-11

Frequently Asked Questions

FEops HEARTguide is a cloud-based procedure planning platform that combines digital twin technology with AI-based anatomical analysis and predictive simulation. It provides physicians with unprecedented insights into how transcatheter structural heart devices will interact with a patient's unique anatomy pre-operatively, aiming to improve clinical outcomes and procedural efficiency for interventions like LAAo and TAVI.
The platform creates patient-specific virtual replicas, or 'digital twins,' from cardiac CT scans, which are then analyzed using AI to provide precise anatomical measurements. This enables physicians to simulate different treatment scenarios, predict device-anatomy interaction, and select the optimal device size and position for personalized patient care, thereby reducing potential complications.
FEops HEARTguide primarily supports planning for Left Atrial Appendage Occlusion (LAAo) and Transcatheter Aortic Valve Implantation (TAVI) procedures. It has received FDA clearance for its AI-based anatomical analysis capabilities and LAAo planning in the US, and holds CE mark approval for both LAAo and TAVI workflows in the EU, UK, Canada, and Australia.
Clinical evidence indicates that FEops HEARTguide improves procedural efficiency by reducing procedural time, fluoroscopy time, and contrast usage, and can lead to a reduction in the number of devices and repositioning needed. For patients, this translates to improved outcomes such as higher rates of complete LAA closure, reduced peridevice leaks, and better-informed decisions for complex TAVI cases, including lifetime management considerations.
As a cloud-based platform, FEops HEARTguide is designed with robust security measures to ensure the confidentiality and integrity of patient data. The company adheres to stringent national and international privacy legislations, including GDPR and HIPAA, to protect sensitive health information.
FEops operates on a service-based business model where clinicians upload patient data, and FEops performs the anatomical analysis and predictive simulations, delivering the results back to the customer. The platform offers email support and features a collaborative environment that allows secure sharing of cases with peers and industry partners.
FEops nv was acquired by Materialise in 2024, significantly enhancing its stability and expanding its cardiovascular capabilities. The company maintains strategic partnerships, such as with TeraRecon for commercialization of its LAAo workflow in the US, and continues to innovate and extend its platform to new applications within structural heart disease.

Related Companies

CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]

Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]

OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]

Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]

MedTalk AI is an Australian-based healthcare AI company focused on streamlining clinical documentation for physicians and other healthcare professionals. The company’s flagship product is an ambient AI medical scribe that listens to real clinical conversations and converts them into structured, accurate notes in real-time. This technology aims to free clinicians from the burden of manual […]

allergoSMART is a healthcare AI company that offers the world’s first AI-based complete solution for personalized mite allergen avoidance. The company’s system, allergoSMART, provides a unique AI digital solution for individuals with dust mite allergies, combining targeted prevention and treatment through comprehensive home environment optimization. [3] It integrates symptom tracking, telemedicine, and air purification into […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.